Tandem Diabetes Care’s (TNDM) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Tandem Diabetes Care (NASDAQ:TNDM) in a research note published on Friday morning, Benzinga reports. The brokerage currently has a $50.00 price target on the medical device company’s stock, up from their prior price target of $35.00.

Several other equities research analysts also recently commented on the company. StockNews.com upgraded Tandem Diabetes Care from a sell rating to a hold rating in a report on Friday, April 19th. Stifel Nicolaus upped their price objective on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a buy rating in a report on Tuesday, April 23rd. Robert W. Baird lifted their price objective on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a neutral rating in a report on Friday. SVB Leerink upgraded shares of Tandem Diabetes Care from a market perform rating to an outperform rating and upped their target price for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Finally, Leerink Partnrs upgraded Tandem Diabetes Care from a market perform rating to an outperform rating in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of Moderate Buy and a consensus price target of $43.80.

Tandem Diabetes Care Stock Down 2.7 %

Shares of NASDAQ TNDM opened at $43.50 on Friday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. The company’s fifty day simple moving average is $32.58 and its 200 day simple moving average is $26.35. Tandem Diabetes Care has a 12-month low of $13.82 and a 12-month high of $47.00.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. On average, equities analysts predict that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Tandem Diabetes Care in the first quarter worth about $5,227,000. Quantbot Technologies LP purchased a new stake in shares of Tandem Diabetes Care in the first quarter worth about $710,000. Duality Advisers LP purchased a new stake in shares of Tandem Diabetes Care in the first quarter worth about $940,000. Texas Permanent School Fund Corp lifted its holdings in shares of Tandem Diabetes Care by 1.6% in the first quarter. Texas Permanent School Fund Corp now owns 56,910 shares of the medical device company’s stock worth $2,015,000 after buying an additional 915 shares in the last quarter. Finally, RiverPark Advisors LLC lifted its holdings in shares of Tandem Diabetes Care by 1,008.4% in the first quarter. RiverPark Advisors LLC now owns 10,153 shares of the medical device company’s stock worth $360,000 after buying an additional 9,237 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.